Recent studies on HNSCC have found that mutations in TP53 are associated with high TMB and low overall survival rates, and coincidently HNSCC patients with high TMB have higher response rates to immune checkpoint therapy (23, 24). Here, TP53 is linked to head and neck squamous cell carcinoma.